Ligand Pharmaceuticals

LGND | NASDAQ | 0 Followers
$102.19 +1.27% $1.28
Follow
Overview Metrics Financials
Loading...

Fair Price

$72.17
Overvalued by 67.7%
To display the fair price of a share, you need to be a member of Bulios Black.

Profile

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is a San Diego-based biopharmaceutical company specializing in the development and acquisition of technologies that support the discovery and development of new therapeutics. The company generates revenue by licensing its Captisol® platform to biotech partners and manages a diversified portfolio of over 100 licensed programs across various therapeutic areas and development stages. In July 2024, Ligand announced the acquisition of APEIRON Biologics AG for $100 million, securing royalty rights to the commercial oncology drug QARZIBA®, designed for the treatment of high-risk neuroblastoma. Financial results for the second quarter of 2024 showed revenues of $41.5 million, surpassing analysts' expectations. The company plans to release its fourth quarter and full-year 2024 financial results on February 27, 2025.

Feed

There are no posts to show right now.
Don't have an account? Join us

Log in to Bulios

Continue with Google
Continue with Apple
Continue with Facebook
Or use email and password
Reset password
Already a member? Log in

Create Bulios profile

Continue with
Or use email and password
You can use lowercase letters, numbers, and underscores

Why Bulios?

One of the fastest growing investor communities in Europe

Comprehensive data on thousands of stocks from around the world

Current information from global markets and individual companies

Education and exchange of investment experience among investors

Fair prices, portfolio tracker, stock screener and other tools
Menu StockBot
Tracker
Upgrade